Key Takeaways:
- FDA will ask a panel of outside advisers to review seven peptides at a meeting in July, specifically whether they should be added to a list of substances that can be safely produced by pharmacies
- In September 2023, the Biden administration identified a group of peptides with the potential to pose "significant safety risks" and designated them in a category that prohibited compounding pharmacies from making them. Now, the FDA is moving to reclassify 12 of those peptides
- "I'm a big fan of peptides," Kennedy told Rogan. "I've used them myself and with really good effect on a couple of injuries."
FDA Announces July Review of Peptide Restrictions
The Food and Drug Administration will hold a meeting this summer to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular among wellness influencers, fitness gurus and celebrities. The announcement, made Wednesday April 15, represents a dramatic policy reversal from the Biden administration's approach to these unproven compounds.
The meeting announcement Wednesday follows repeated pledges by Health Secretary Robert F. Kennedy Jr. to loosen regulations on peptides, which are often pitched as a quick way to build muscle, heal injuries or appear younger. There's little research behind those claims and most peptides have not been reviewed for safety by the FDA.
The July meetings will focus on some of the most popular among influencers, such as BPC-157, which is marketed to heal injuries and reduce inflammation. The meetings will take place July 23 and 24. Another will be held before the end of February 2027.
Biden-Era Restrictions Under Review
Under President Joe Biden, the FDA added nearly 20 peptides to the federal list of substances that should not be produced by compounding pharmacies — businesses that mix medications that aren't available from drugmakers. At the time, the FDA's panel of pharmacy advisers voted overwhelmingly that the peptides did not meet the criteria for substances that can be safely compounded.
The Trump administration is now taking the opposite approach. The FDA said in a federal notice Wednesday it will ask a panel of outside advisers to review seven peptides at a meeting in July, specifically whether they should be added to a list of substances that can be safely produced by pharmacies. In the meantime, the agency said it would soon remove the chemicals from a restrictive list reserved for unapproved, high-risk drugs.
Peptides are short chains of amino acids that form the basis of a number of approved medicines, including insulin and popular GLP-1 medications like semaglutide and tirzepatide. But there are also many peptides that are not backed by rigorous research and are available through compounding pharmacies, whose purpose is to tailor medications for patients with specific needs.
RFK Jr.'s Personal Advocacy Drives Policy Change
The regulatory shift stems directly from Kennedy's personal enthusiasm for these treatments. The proposed peptide reclassification is the latest move by Health and Human Services Secretary Robert F. Kennedy Jr. to move the American health system toward his own MAHA vision. Kennedy is a "big fan" of peptides and has taken them himself, he told podcaster Joe Rogan in February.
Kennedy has discussed using peptides for his own injuries. And some major supporters of his Make America Healthy Again movement are big proponents of them, including Gary Brecka, a self-described "longevity expert" who sells various peptide formulas through his website.
Critics question whether this personal interest compromises scientific objectivity. Given Kennedy's statements, Lurie said it was doubtful the drugs would receive real scrutiny from FDA. "Everybody knows the outcome that the secretary wants," Lurie said. "I don't believe for one moment that what's going on here is an honest investigation of whether these products should be compounded."
Safety Concerns and Market Impact
Health experts warn about potential risks. "The Wild West is about to become wilder," said Dr. Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest. In an interview, Lurie said allowing peptides on the market without clinical testing poses a "profound threat" to FDA's decades-old system for vetting drugs. "I don't see why one would take the path of a proper drug approval if there is now this less rigorous, alternative path to market," he said.
Physicians say peptides could increase health risks, including cancer, because of the way they stimulate hormone production and the formation of tissues. There's also concern about the effects of taking multiple peptides at the same time, and how they'd interact with drugs. "The FDA should ban these peptides from being imported, from being used, and force the companies that are making huge amounts of profit on them to do the proper studies," said Eric Topol, executive vice president of Scripps.
Meanwhile, telehealth companies are positioning for a potential boom. Hims purchased a peptide manufacturing facility last year. The anticipated FDA changes sent Hims shares soaring nearly 50% in the span of a week. Hims & Hers, a telehealth company that capitalized on shortages of GLP-1 drugs to supply cheaper compounded versions, hailed the decision. "The FDA's plans to more clearly define the regulatory status of several peptides is an important step toward moving these treatments out of the gray market, and into more trusted channels overseen by vetted healthcare professionals," CEO Pat Carroll said.
Current Black Market Concerns
Proponents argue the restrictions created dangerous underground markets. Because of FDA's prohibition, peptide fans often purchase them from overseas and from websites that offer research-grade peptides that aren't intended for use by humans. All of this has raised a host of new risks for consumers. "The reality is people are getting them, and they're getting them from very disreputable sources where they don't know what's in them," says Dr. Myles Spar, an integrative medicine specialist and chief medical officer at WndrHLTH. "They're injecting themselves with things that are potentially dangerous."
Some in the compounding industry argue that FDA's restrictions have given rise to an illicit market of imported chemicals from China and other countries, which are not subject to U.S. drug standards. Kennedy has echoed those concerns. "With the gray market you have no idea if you're getting a good product," Kennedy told Rogan. "And a lot of this stuff that we've looked at is very, very substandard."
What This Means for You
The FDA's July meetings could significantly expand access to peptide treatments through legitimate telehealth providers and compounding pharmacies. However, Unlike brand-name GLP-1s, most peptides haven't gone through clinical trials. The current boom in unregulated peptides has been distorted by profit‑driven influencers who don't adequately address the potential dangers.
If you're considering peptide treatments, waiting for the regulatory dust to settle might be wise before making decisions. The July meetings will provide clearer guidance on which peptides may become legally available through proper medical channels. For now, avoid purchasing peptides from unregulated online sources, which pose significant safety risks. When these treatments do become available through legitimate channels, working with qualified healthcare providers through established GLP-1 clinics can help you properly assess risks and benefits for your specific situation.
Understanding the costs of compounded therapies will also become crucial as this market evolves. The potential regulatory changes could affect pricing and insurance coverage for peptide treatments in the coming months.
Sources
- NBC News - RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicals - Associated Press report on FDA's July meeting announcement
- PBS News - FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters - Coverage of regulatory policy shift
- CBS News - FDA will consider easing restrictions on peptides as RFK Jr. calls himself a "big fan" - Details on Kennedy's personal advocacy
- BioPharma Dive - FDA moves toward easing restrictions on certain peptides - Industry perspective on regulatory changes
- Axios - RFK Jr.'s peptide push could become next wellness boom - Analysis of market impact and telehealth opportunities